产品名称
卡马西平, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
SMILES string
NC(=O)N1c2ccccc2C=Cc3ccccc13
InChI key
FFGPTBGBLSHEPO-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
carbamazepine
manufacturer/tradename
USP
mp
191-192 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
抗惊厥药；GABAA受体苯二氮卓调节位点的配体。钠离子通道抑制剂。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Carbamazepine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Carbamazepine Extended-Release Tablets
- Carbamazepine Oral Suspension
- Carbamazepine Tablets
- Oxcarbazepine
- Oxcarbazepine Oral Suspension
- Oxcarbazepine Tablets
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3
target_organs
Central nervous system
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
Wimonchat Tangamornsuksan et al.
JAMA dermatology, 149(9), 1025-1032 (2013-07-26)
The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
Philip J Wiffen et al.
The Cochrane database of systematic reviews, (1)(1), CD005451-CD005451 (2011-01-21)
Carbamazepine is used to treat chronic neuropathic pain. Evaluation of analgesic efficacy and adverse effects of carbamazepine for acute and chronic pain management (except headaches). Randomised controlled trials (RCTs) of carbamazepine in acute, chronic or cancer pain were identified, searching
Anna Jurado et al.
Chemosphere, 115, 47-53 (2014-02-25)
This paper deals with urban groundwater contaminated with carbamazepine (CBZ) and five of its human metabolites in Barcelona. Groundwater samples were accordingly collected in the aquifers of Poble Sec and Besòs River Delta. Higher concentrations and more compounds were found
Sandeep Grover et al.
Pharmacogenetics and genomics, 24(2), 94-112 (2013-12-18)
A considerable heterogeneity exists in the literature on the role of different HLA alleles in carbamazepine (CBZ)-induced cutaneous adverse drug reactions (cADRs) of varying severity among diverse ethnic groups. The aim of the present study was to understand and summarize
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持